2024
PHENOTYPING REPAIR AFTER ACUTE KIDNEY INJURY: PRECISION MEDICINE TO CLINICAL TRIALS.
Parikh C, Hernandez J. PHENOTYPING REPAIR AFTER ACUTE KIDNEY INJURY: PRECISION MEDICINE TO CLINICAL TRIALS. Transactions Of The American Clinical And Climatological Association 2024, 134: 37-46. PMID: 39135588, PMCID: PMC11316880.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseKidney injuryEpisodes of acute kidney injuryAssociated with long-term riskLong-term risk of readmissionLong-term sequelaeRepair biomarkersRisk of readmissionSubclinical inflammationPreclinical studiesUrine biomarkersResearch biopsiesDeceased donor kidneysClinical trialsKidney diseaseBlood pressureMedical managementDonor kidneysPragmatic clinical trialsKidney tissueTherapeutic developmentOrgan allocationPrecision medicineKidney
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients